Peptide Research Evidence Guide: Human Studies and Safety

If you are reading about peptides after seeing an ad or a sales video, you want to know one thing before anything else: what do the human studies actually show? Many peptides talked about online are still at a very early stage of research, and most of the work on them has been done in cells and animals. The clearest example is BPC-157, where a narrative review of BPC-157 studies reports that its clinical data come from fewer than 30 people across three uncontrolled pilot studies. This guide covers what was tested, the US federal policy on six peptides published October 30, 2026, the risks, the checks to run before you pay, and the questions to settle first.

Disclosure: this is editorial content from Clinical Research Explained, written for education. Links on this page point to references and to our own guides.

Quick facts (checked 2026-11-02)

What peptides are, and what this policy covers

Peptides are the building blocks of more complex proteins. As NBC News reports from AP, drug companies have brought several peptides to market as medications, including mainstay treatments for diabetes and weight loss. The peptides in this policy are different: “the ones at issue here haven’t gone through that rigorous vetting process.”

The policy is about compounding. Compounding is generally the practice in which a licensed pharmacist or physician mixes ingredients into a medication for one patient, as described in FDA’s compounding basics slides.

HHS says it “does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A, in the circumstances the policy lists.” Appendix A names the six peptides. Enforcement discretion is not FDA approval.

Adding peptides to the 503A bulks list would take federal rulemaking, a process that NBC News reports could take years. The policy covers each peptide in one form and the routes below.

The route list is as summarized by LegitScript, a certification organization that reviews merchants.

Who may fit, and who should pause

The policy’s frame fits a patient who has a prescription written for them as an individual, filled by a state-licensed pharmacy, for one of the six peptides in the named form and route. The prescription must be patient-specific, which is one of the policy’s conditions.

Pause if any of these apply:

• The product is sold as a research chemical or as a supplement. BakerHostetler notes the policy does not apply to products sold that way.
• The product combines peptides. The policy requires a single active ingredient.
• If the product is an oral form other than BPC-157 acetate or KPV acetate, it falls outside the policy. LegitScript’s FAQ says only those two oral forms are addressed.
• If the product comes in an injector pen, it does not meet the device condition. The policy limits the delivery device to an FDA 510(k)-cleared syringe.
• It is a peptide outside the six. HHS’s policy covers only those six.

How the offer works

NBC News reports that Hims & Hers and Noom have each said they plan to offer peptides to customers if the federal government eases access. LegitScript’s summary of the policy lists 10 conditions a compounder must meet. The main ones are:

• A single active ingredient, with the specific identity and route stated.
• A certificate of analysis (COA) from a facility registered under section 510, and an original manufacturer that is FDA-registered and follows current good manufacturing practice, with its physical location printed on the COA.
• Reporting of serious adverse events and product quality problems to FDA and the relevant states.
• The label wording “This is a compounded drug product. Not for resale.”
• For oral preparations, documentation that the specific formulation reaches adequate oral bioavailability in humans.
• Delivery devices limited to FDA 510(k)-cleared syringes.

What the research shows

Here is the research, split into established facts, what one seller says, our reading, and the open questions.

Established facts

• A narrative review of BPC-157 reports: “Available clinical data derive from fewer than 30 subjects across three uncontrolled pilot studies, none of which employed standardized pharmaceutical preparations.” It also reports a plasma half-life under 30 minutes, confirmed in a preclinical study in two species and a preliminary two-subject human pilot, against effects it describes as lasting hours to days. The review is a narrative design with no formal quality assessment.
• FDA staff briefing materials, as reported by The Hill, concluded: “there is a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating [ulcerative colitis].”
• The Hill reports that staff reached the same conclusion for all six peptides, finding there was not enough evidence to support adding any of them to the compoundable list.
• ABC News reports that FDA staff scientists unanimously opposed adding every peptide to the list, and that the advisory vote was narrow. The advisory meeting of July 23–24, 2026 is described in a Legal 500 analysis of the policy’s review.
• For study design, peptides.fyi notes that for BPC-157, essentially all supporting data come from cell cultures and animal models. It puts the point this way: “A dramatic result in cells is a hypothesis. A dramatic result in a large, well-run human trial is evidence.”
• A 2023 Cochrane blinding review by Pitre and colleagues found low-certainty evidence that trials lacking blinding may slightly overestimate treatment effects.
• A 2019 Biostatistics analysis by Wong, Siah and Lo estimated that about 14% of drug-development programs reaching Phase I ultimately gain approval, and roughly 3.4% for cancer, as summarized by peptides.fyi.

For a plain walk-through of what peptide trials found, read what peptides trials found (our research library).

What the seller says

The Peptide Research Handbook, a seller-side site, describes itself as “An educational platform built to simplify peptide research, combined with a quality-focused supply model for serious buyers and long-term partners.” Its homepage lists “3rd Party Testing Available” and says “Independent testing and verification available upon request for transparency.” The same page uses “Research Supplies” and “Serious Research Buyers.” Because the policy excludes products sold as research chemicals or supplements, that framing is one of the first things to check.

Our reading

For BPC-157, the human data are small pilot work. For all six, FDA’s own staff found the evidence insufficient, while an advisory panel voted the other way. ABC News reports that six of the eight recently appointed members run clinics that offer peptides, which is worth weighing when you read the panel’s votes.

Open questions

• How the six behave in people, and whether a given oral form reaches the body. The policy requires documentation for oral forms.
• Whether the policy changes after comments close on November 13, 2026, or after federal rulemaking.
• Whether a given pharmacy will carry them, since LegitScript says advertising platforms and payment providers set their own requirements.

Ask your prescriber which of these points applies to the product they would prescribe.

What is the risk of taking peptides?

For the side effects of a specific product, ask your prescriber what is known about that exact peptide and form. Under the policy, serious adverse events must be reported to FDA and the states.

On what not to mix them with: LegitScript reads the single-ingredient rule as ruling out combinations, such as BPC-157 with TB-500 or with semaglutide. Ask your pharmacist about anything else you already take.

Is the seller legit, and how do you check?

A ranking of the “most legit” peptide company cannot settle this for you. What separates one seller from another is whether it passes these checks.

Who is the seller?

• Is it a State-licensed pharmacy, a federal facility, or a licensed physician? Ask for the name and license number.
• Is the product one of the six, in the named form and route, compounded for you under a prescription?
• Does it come with a certificate of analysis from a facility registered under section 510?
• Does the label read “This is a compounded drug product. Not for resale.”?
• Is the original manufacturer FDA-registered, with its location printed on the COA?
• Is the product sold as a research chemical or supplement? Those sales fall outside the policy.

Famous names and influencers

NBC News reports that some of the biggest MAHA figures sell peptide injections and supplements. A famous name is not a check. Look for the licensed pharmacy and prescriber on the order itself.

Certification and advertising

LegitScript updated its certification review effective November 2, 2026. It says advertising platforms and payment providers set their own requirements, and that those may differ from its own timeline.

If a particular seller is on your shortlist, the merit sciences peptides ingredients guide covers one seller’s ingredients, amounts and research.

What it costs, and what you commit to

Prices and bundles change, so check today’s price directly with the company or with the pharmacy that would fill your prescription. Get these in writing before you pay.

Refund and renewal terms are set by each seller, so read them on the order page before you pay. For a closer look at one seller’s refund and contact details, read synthesis peptides legit or scam.

Alternatives, including FDA-reviewed medicines and waiting

To see which peptides have FDA approval, read what peptides are fda approved.

Decision questions that settle it

How to verify before you pay

1. Ask your prescriber whether the peptide is one of the six, in the form and route they would prescribe.
2. Confirm the pharmacy’s state license and whether it operates under section 503A.
3. Request the COA and check the manufacturer and its location.
4. Read the label for the required compounded-drug wording.
5. Search the peptide name on PubMed, the National Library of Medicine index and on ClinicalTrials.gov registry for human studies, and note the phase.
6. Get the price, renewal and refund terms in writing.

Guides that go deeper

To check how a seller operates, read synthesis peptides a scam or legit, which covers contact details, certificates of analysis, refunds and risks.

For the list of peptides the policy names, read hhs 503a peptide list. For the safety rules that apply to unapproved compounding, read hhs unapproved peptides compounding safety.

For a broader look at the side effects and safety studies, read are peptides dangerous side effects. For a general introduction to what peptides are, read exploring peptides.

Your other questions, answered briefly

Are peptides considered a drug?

In the regulatory sense, yes. HHS’s policy refers to these peptides as bulk drug substances, the active ingredients of drugs, and the products made from them as compounded drug products. A 2018 Federal Register notice describes bulk drug substances as active pharmaceutical ingredients.

Are peptides like Ozempic?

None of the six is an FDA-approved diabetes or weight-loss medicine like Ozempic. The Hill’s report says the advisory vote covered uses such as insomnia, obesity and wound healing, and FDA staff found too little evidence on all six. AP reports that drug companies have brought several peptides to market for those uses, but the six named here have not gone through that vetting.

What are the top three peptides?

The policy names six, not three: BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c. BPC-157 is the one whose human studies are described above.

What peptide does Joe Rogan take?

What any celebrity takes is not something the research or the policy addresses. AP reports that peptide injections have become popular among followers of Health Secretary Robert F. Kennedy Jr. and other wellness influencers, which is a reason to check the seller, not to copy someone else.

Are peptides safer than steroids?

The studies above cover peptides only. A fair comparison depends on the specific peptide, the form and your prescriber’s plan, so bring the question to your prescriber.

Can peptides fail a drug test?

If a drug test matters to you, ask the testing body which substances it screens for before you take any product.

Can peptide injections help with wrinkles?

The policy is about compounding conditions, not about what any peptide does for skin. To check a wrinkle claim, search the peptide on PubMed and ClinicalTrials.gov for human trials in skin.

How to use peptide serum?

Start with the product label. For any peptide, dosing and use steps belong to your prescriber, so ask them directly.

Where do I research peptides?

Start with PubMed for published studies and ClinicalTrials.gov for registered human trials. The peptides.fyi guide on reading peptide research explains the difference between animal and human studies.

How do I get a prescription?

Ask a licensed prescriber. The policy requires a patient-specific prescription, and a state-licensed pharmacy fills it.

By the Clinical Research Explained Editorial Team

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.